Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Precipio Trading Up 2.7 %
PRPO opened at $1.52 on Thursday. The stock has a 50-day moving average price of $1.21 and a 200-day moving average price of $1.23. The company has a quick ratio of 2.47, a current ratio of 2.59 and a debt-to-equity ratio of 0.01. Precipio has a 1 year low of $0.91 and a 1 year high of $4.17.
Precipio (NASDAQ:PRPO - Get Rating) last released its quarterly earnings results on Wednesday, May 11th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $2.45 million for the quarter. Precipio had a negative net margin of 123.12% and a negative return on equity of 46.63%.